Oncotarget is a multidisciplinary, free-access medical journal established in 2010. It was tailored previously towards oncology research but later extended to other fields of research such as cancer, neurodegeneration, atherosclerosis, lymphocytes and neurons, and microbes. Oncotarget publishes weekly journals, and sometimes issues are printed on special demand. The journal’s editors-in-chief are Andrei Gudkov, and Mikhail Blagosklonny, working at the Roswell Park Cancer Institute, have made tremendous contributions towards its growth.
Oncotarget has gradually risen to popularity for the last 6 years because of its insights, punctuality, and constructiveness. And for this reason, it has attracted several peer-reviewed research work from different authors, who wish to heighten their impact in medical research. To this point, two of the editorial board members, Carlo Croce and Andrew Schally (Nobel Prize winner) have published 27 and 10 papers, which is a significant contribution. Follow Oncotarget journal on Twitter.
The chief objectives of Oncotarget are to acquire scientific results to the larger population, maximize the impact of scientific research, facilitate rapid sharing of exceptional discoveries, eliminate boundaries between specialties, and to enhance the use of clinical science to fight disease. Therefore, it plays a vital role in the progress of science to attain its ultimate goal of a life without a disease.
Oncotarget believes that research should be widely available to the public. When scientific results are achieved, these results are made available so that users can see them quickly. Since speed is very important with regards to delivering information, Oncotarget has become one of the best free access medical journals available online. Download output styles at Endnote.com.